Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

KaloBios Pharmaceuticals presents phase I results for KB-004

Dec. 16, 2013

ImmunoCellular Therapeutics reports phase II data for ICT-107

Dec. 16, 2013

Otlertuzumab combined with rituximab shows promise in lymphocytic leukemia

Dec. 13, 2013

Final results presented for glioblastoma multiforme trial of Cotara

Dec. 13, 2013

Treatment phase of MGN-1703 safety trial completed

Dec. 12, 2013

First-in-human phase I study reported for SGN-CD19A

Dec. 10, 2013

CSL enters agreement with Janssen for CSL-362

Dec. 10, 2013

MUC-1 cancer vaccine well tolerated in phase I study

Dec. 9, 2013

OncoMed studies vantictumab combination therapy for pancreatic cancer

Dec. 5, 2013

FDA grants orphan drug designation to Immunomedics' IMMU-132 for SCLC

Dec. 5, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...